Generation of an induced pluripotent stem cell line (TRNDi012-B) from Fibrodysplasia Ossificans Progressiva (FOP) patient carrying a heterozygous mutation c. 617G > A in the ACVR1 gene

Xiuli Huang\textsuperscript{a}, Amanda Roeder\textsuperscript{a}, Rong Li\textsuperscript{a}, Jeanette Beers\textsuperscript{b}, Chengyu Liu\textsuperscript{c}, Jizhong Zou\textsuperscript{b}, Paul B. Yu\textsuperscript{d}, Wei Zheng\textsuperscript{a,\textdagger}

\textsuperscript{a}National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA

\textsuperscript{b}iPSC Core, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA

\textsuperscript{c}Transgenic Core, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA

\textsuperscript{d}Brigham and Women’s Hospital and Harvard Medical School, Division of Cardiovascular Medicine, Boston, MA, USA

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of progressive ossification of skeletal muscle, fascia, tendons, and ligaments. Most FOP cases are caused by a heterozygous c. 617G > A mutation in the \textit{ACVR1} gene which encodes a gain-of-function of bone morphogenetic protein type I receptor. A human induced pluripotent stem cell (iPSC) line was generated from the dermal skin fibroblasts of a FOP patient who carries the c. 617G > A mutation in the \textit{ACVR1} gene. This iPSC line provides an attractive resource for FOP disease modeling.

1. Resource utility

This human induced pluripotent stem cell line is a useful tool for establishing \textit{in vitro} disease model and for applications in drug development to treat FOP.

\textsuperscript{\textdagger}Corresponding author. Wei.Zheng@nih.gov (W. Zheng).

Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Wei Zheng reports financial support was provided by National Center for Advancing Translational Sciences. Wei Zheng reports a relationship with National Center for Advancing Translational Sciences that includes: employment.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.scr.2021.102424.
2. Resource details

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease characterized by congenital malfunctions of great toes and progressive heterotopic ossification of soft tissues, that results in severe restriction of joint function and premature mortality (Kaplan et al., 2009). The majority of FOP patients carry a heterozygous missense mutation (c.617G > A; p.R206H) in the ACVR1 gene, which encodes activin A type I receptor /activin receptor-like kinase 2 (ACVR1/ALK2), a morphogenetic protein (BMP) type I receptor (Shore et al., 2006). The mutation causes a gain-of-function of activation of ACVR1, leading to the transformation of connective tissue and muscle tissue into a secondary skeleton (Hatsell et al., 2015). FOP has a prevalence of approximately 1 in 2 million people worldwide (Baujat et al., 2017). Currently, no approved treatment exists for FOP patients.

In this study, we generated a human iPSC line (TRNDi012-B, also named as NCATS-CL7989) from patient skin fibroblast (GM00513) which was isolated from a 16-year-old female FOP patient carrying a heterozygous mutation (c.617G > A; p.R206H) in ACVR1 gene. (see Table 1). A non-integrating CytoTune-Sendai viral vector kit (A16517, ThermoFisher Scientific) containing OCT3/4, KLF4, SOX2 and C-MYC pluripotency transcription factors was employed to transduce the patient cells using a previously described method (Beers et al., 2015). A single iPSC colony, termed NCATS-CL7989, was isolated and characterized. Fig. 1A show that the iPS cells displayed a standard pluripotent stem cell morphology under phase contrast microscopy and expressed pluripotent markers SOX2, OCT4, NANOG and SSEA4 in the immunocytochemistry assay. In addition, flow cytometric analysis showed that the expression levels of NANOG, SSEA4 and cell surface marker TRA-1-60 were over 98% (Fig. 1B). The mutation (c.617G > A) of the ACVR1 gene in the NCATS-CL7989 iPSC line was confirmed by Sanger sequencing the PCR product harboring the single nucleotide variation (SNV) (Fig. 1C). At passage 7, cells showed a normal karyotype (46, XX), as confirmed by the G-banded karyotyping (Fig. 1D). The Sendai virus vector (Sev) clearance was verified with reverse transcription polymerase chain reaction (RT-PCR) using Sev-specific primers. The Sev vector disappeared at passage 19 (Fig. 1E). The iPSCs was not contaminated with mycoplasma (Supplementary Fig. S1), and 16 loci from NCATS-CL7989 iPSC cells and GM00513 FOP fibroblasts determined by the short tandem repeat (STR) DNA profile were identical (information available from the authors). Furthermore, the pluripotency of this iPSC line was confirmed by a teratoma formation experiment that exhibited its ability to differentiate into all three germ layers (Ectoderm, Mesoderm and Endoderm) in vivo (Fig. 1F).

3. Materials and methods

3.1. Cell culture

The FOP patient fibroblasts (GM00513, Coriell Cell Repository) were maintained in DMEM containing 15% fetal bovine serum (HyClone). NCATS-CL7989 iPSCs were cultured in StemFlex™ medium (Thermo Fisher Scientific) on Matrigel (Corning, Cat# 354277)-coated plates at 37 °C in humidified air with 5% CO₂. The cells were passaged with 0.5 mM Ethylenediaminetetraacetic acid (EDTA) at 1:6 ratio when they reached 80% confluency.
3.2. Reprogramming of human skin fibroblasts

Using a CytoTune™-iPS 2.0 Sendai Reprogramming Kit (A16517, ThermoFisher Scientific) containing c-MYC, KLF4, OCT3/4, and SOX2 pluripotency transcription factors, the FOP patient fibroblasts (GM00513) were reprogrammed to iPSCs as previously reported (Beers et al., 2015).

3.3. Mutation analysis

Genomic mutation analysis was contracted to Codex BioSolutions (Gaithersburg, MD, USA). Briefly, genomic DNA was extracted from the cell pellet of FOP iPSCs with a PureLink™ Genomic DNA Mini kit (K182002, ThermoFisher Scientific). The mutation in the ACVR1 gene was analyzed by a DNA sequencing of PCR amplified product. With the specific primers listed in Table 2 and JumpStart Taq ReadyMix (P2893, Sigma-Aldrich), 40 cycles of PCR were performed with annealing temperature at 56 °C and extension time of 70 s. Sanger sequencing analysis was then employed for genotyping the heterozygous mutation, resulting in confirmation of the mutation of c. 617G > A in the ACVR1 gene.

3.4. Immunocytochemistry staining

The iPSCs in a 96-well plate were fixed in 4% paraformaldehyde for 15 min followed by a plate wash with Dulbecco’s phosphate-buffered saline (DPBS) and cell permeabilization with 0.1% Triton X-100 in DPBS for 15 min. The Image-iT™ FX Signal Enhancer (I36933, ThermoFisher Scientific) was added to the fixed cells and incubated for 40 min at room temperature. The primary antibodies against SOX2, OCT4, NANOG and SSEA4 diluted in the Image-iT™ FX Signal Enhancer were then added and incubated at 4 °C overnight. After washing with DPBS, a corresponding secondary antibody conjugated with Alexa Fluor 488 or Alex Fluor 594 as these listed in Table 2 was added to the cells for 1 h incubation at room temperature. After the cells were washed and stained with Hoechst 33342 for 15 min, an INCell Analyzer 2200 imaging system (GE Healthcare) was used imaging analysis with 20X objective lens and Texas Red, FITC and DAPI filter sets.

3.5. Flow cytometry analysis

The iPSCs were harvested using TrypLE Express enzyme (12605010, ThermoFisher Scientific) and fixed with 4% paraformaldehyde for 10 min at room temperature. After the cells were washed with DPBS and permeabilized with 0.2% Tween-20 in DPBS for 10 min at room temperature, fluorophore conjugated antibodies (Table 2) were incubated with the cells for 1 h at 4 °C on a shaker. A BD AccuriC6 Flow Cytometer (BD Biosciences) was used for the flow cytometry analysis.

3.6. G-banded karyotyping

The G-banding karyotype analysis of the iPSC cells at the passage-7 was performed at the WiCell Research Institute (Madison, WI) using a standard cytogenetic protocol. Cells on a slide were incubated with ethidium bromide and colcemid, followed by a fixation in hypotonic solution. Leishman’s stain was then used to stain the metaphase cells. A total of 20 randomly selected metaphases were analyzed.
3.7. Short tandem repeat (STR) DNA profile analysis

The Short Tandem Repeat (STR) analysis of original patient fibroblasts and derived iPSCs was carried out by the Translational Research Initiatives in Pathology (TRIP) Laboratory at University of Wisconsin–Madison. A PowerPlex® 16 HS System (DC2101, Promega) was employed in multiplex PCR to amplify fifteen STR loci (D5S818, D13S317, D7S820, D16S539, VWA, TH01, TPOX, CSF1PO, D18S51, D21S11, D3S1358, D8S1179, FGA, Penta D, Penta E) and Amelogenin (AMEL, a gender determining marker). Capillary electrophoresis of the PCR products was carried out on an ABI 3500xL Genetic Analyzer using the Internal Lane Standard 600 (ILS 600) (Promega). A GeneMapper® v 4.1 software (Applied Biosystems) was used for data analysis.

3.8. Mycoplasma detection

Using a MycoAlert™ Mycoplasma Detection Kit (LT07-218, Lonza), mycoplasma detection was performed following the manufacturer’s instruction. Ratio B/A < 0.9 indicates mycoplasma negative, Ratio between 0.9 and 1.2 indicates mycoplasma ambiguous results, and Ratio B/A > 1.2 indicates mycoplasma positive.

3.9. Testing for Sendai reprogramming vector clearance

Total RNA was isolated from the iPSCs (NCATS-CL7989) at passage 19 using a RNeasy Plus Mini Kit (74034, Qiagen). The total RNA from human fibroblasts (Coriell Institute, GM05659) transduced with Sendai virus for 4 days was used as a positive control. A SuperScript™ III First-Strand Synthesis SuperMix (18080400, ThermoFisher Scientific) was used for the cDNA synthesis from 1 μg RNA and random hexamers, followed by a PCR (primers listed in Table 2) performed using a Platinum II Hot-Start PCR Master Mix (14000012, ThermoFisher Scientific) with the following program: 94 °C, 2 mins; 30 cycles of (94 °C, 15 s, 60 °C, 15 s and 68 °C, 15 s). The PCR products were loaded to an E-Gel® 1.2% with SYBR Safe™ gel, ran at 120 V electric field, and imaged by G: Box Chemi-XX6 gel doc system (Syngene, Frederick, MD).

3.10. Teratoma formation assay

After the patient iPSCs (NCATS-CL7989) were dissociated with DPBS containing 0.5 mM EDTA, the cells (approximately $1 \times 10^7$) were resuspended in 400 μl culture medium supplied with 25 mM HEPES pH 7.4. The cells, stored on ice prior to injection, were mixed with 200 μl of cold Matrigel (354277, Corning) and injected subcutaneously into NSG mice (JAX No. 005557) at 150 μl per injection site. Visible tumors were removed after 6–8 weeks that were fixed in 10% Neutral Buffered Formalin, and then embedded in paraffin for staining with hematoxylin and eosin.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgement

We thank Dr. Zu-xi Yu of the pathology Core of National Heart, Lung and Blood Institute, National Institutes of Health for sectioning and staining of the teratoma, and the Research Service Section at National Center for...
Advancing Translational Sciences for mycoplasma testing service. This work was supported by the Intramural Research Program at the National Center for Advancing Translational Sciences, National Institutes of Health, USA.

References

Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, Delai P, Fastnacht-Urban E, Forman SJ, Gillessen-Kaesbach G, Hoover-Fong J, Koster B, Pauli RM, Reardon W, Zaidi SA, Zasloff M, Morhart R, Mundlos S, Groppe J, Shore EM, 2009. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum. Mutat. 30, 379–390. [PubMed: 19085907]

Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS, 2006. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat. Genet. 38, 525–527. [PubMed: 16642017]

Hatsell SJ, Idone V, Wolken DM, Huang L, Kim HJ, Wang L, Wen X, Nannuru KC, Jimenez J, Xie L, Das N, Makhouli G, Chernomorsky R, D’Ambrosio D, Corpina RA, Schoenherr CJ, Feeley K, Yancopoulos Yu PBGD, Murphy AJ, Economides AN, 2015. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci. Transl. Med. 7, 303ra137.

Baujat G, Choquet R, Bouee S, Jeanbat V, Courouve L, Ruel A, Michot C, Le Quan Sang KH, Lapidus D, Messienc C, Landais P, Cormier-Daire V, 2017. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet. J. Rare Dis. 12, 123. [PubMed: 28666455]

Beers J, Linask KL, Chen JA, Siniscalchi LI, Lin Y, Zheng W, Rao M, Chen G, 2015. A cost-effective and efficient reprogramming platform for large-scale production of integration-free human induced pluripotent stem cells in chemically defined culture. Sci. Rep. 5, 11319. [PubMed: 26066579]
Fig. 1.
Characterization of NCATS-CL7989 iPSC line. (A) Left: Phase contrast image of NCATS-CL7989 colonies. Right: Immunofluorescence images of iPSCs positive for stem cell markers: SOX2, OCT4, NANOG and SSEA4. Nucleus is labelled with Hoechst 33342 (blue). (B) Flow cytometry analysis of pluripotency protein markers: TRA-1–60, NANOG and SSEA4. (C) Detection of heterozygous gene mutation of c.617G > A in the ACVR1 gene. (D) Cytogenetic analysis showing a normal karyotype (46, XX). (E) RT-PCR confirmation for the clearance of the Sendai virus from reprogrammed cells. Sendai virus
vector transduced fibroblasts was used as a positive control. (F) Pathological analysis of teratoma from NCATS-CL7989 iPSC showing a normal ectodermal, mesodermal and endodermal differentiation.
# Table 1

Characterization and Validation.

| Classification          | Test                        | Result                                      | Data                        |
|-------------------------|-----------------------------|---------------------------------------------|-----------------------------|
| Morphology              | Photography                 | Normal                                      | Fig. 1 Panel A              |
| Phenotype               | Immunocytochemistry         | SOX2, OCT4, NANOG, SSEA-4                   | Fig. 1 Panel A              |
|                         | Flow cytometry              | TRA-1-60 (99.79%)                          | Fig. 1 Panel B              |
|                         |                             | NANOG (99.84%)                             |                             |
|                         |                             | SSEA4 (98.55%)                             |                             |
| Genotype                | Karyotype (G-banding) and resolution | 46XX Resolution: 425–500                   | Fig. 1 Panel D              |
| Identity                | Microsatellite PCR (mPCR) OR | Not performed                              | N/A                         |
|                         | STR analysis                | 16 sites tested; all sites matched          | Available from the authors  |
| Mutation analysis (IF APPLICABLE) | Sequencing                | ACVR1, c.617G > A                          | Fig. 1 Panel C              |
|                         | Southern Blot OR WGS        | N/A                                        | N/A                         |
| Microbiology and virology | Mycoplasma                  | Mycoplasma testing by luminescence.         | Supplementary Fig. S1       |
|                         |                             | Negative                                    |                             |
| Differentiation potential | Teratoma formation         | Teratoma with three germ layers: Ectoderm, Mesoderm and Endoderm | Fig. 1 Panel F              |
| Donor screening (OPTIONAL) | HIV 1 + 2 Hepatitis B, Hepatitis C | N/A                                        | N/A                         |
| Genotype additional info (OPTIONAL) | Blood group genotyping       | N/A                                        | N/A                         |
|                         | HLA tissue typing           | N/A                                        | N/A                         |


### Table 2

**Reagents details.**

| Antibodies used for immunocytochemistry/flow-cytometry | Antibody | Dilution | Company Cat # and RRID |
|-------------------------------------------------------|----------|----------|------------------------|
| Pluripotency Markers                                  | Mouse anti-SOX2 | 1:50     | R & D systems, Cat# MAB2018, RRID: AB_358009 |
| Pluripotency Markers                                  | Rabbit anti-NANOG | 1:400    | Cell signaling, Cat# 4903, RRID: AB_10559205 |
| Pluripotency Markers                                  | Rabbit anti-OCT4 | 1:400    | Thermo Fisher, Cat# A13998, RRID: AB_2534182 |
| Pluripotency Markers                                  | Mouse anti-SSEA4 | 1:1000   | Cell signaling, Cat# 4755, RRID: AB_1264259 |
| Secondary Antibodies                                 | Donkey anti-Mouse IgG (Alexa Fluor 488) | 1:400    | Thermo Fisher, Cat# A21202, RRID: AB_141607 |
| Secondary Antibodies                                 | Donkey anti-Rabbit IgG (Alexa Fluor 594) | 1:400    | Thermo Fisher, Cat# A21207, RRID: AB_141637 |
| Flow Cytometry Antibodies                            | Anti-Tra-1-60-DyLight 488 | 1:50     | Thermo Fisher, Cat# MA1-023-D488X, RRID: AB_2536700 |
| Flow Cytometry Antibodies                            | Anti-Nanog-Alexa Fluor 488 | 1:50     | Millipore, Cat# FCABS352A4, RRID: AB_10807973 |
| Flow Cytometry Antibodies                            | Anti-SSEA-4-Alexa Fluor 488 | 1:50     | Thermo Fisher, Cat# 53-8843-41, RRID: AB_10597752 |
| Flow Cytometry Antibodies                            | Mouse-IgM-DyLight 488 | 1:50     | Thermo Fisher, Cat# MA1-194-D488, RRID: AB_2536969 |
| Flow Cytometry Antibodies                            | Rabbit IgG-Alexa Fluor 488 | 1:50     | Cell Signaling, Cat# 4340S, RRID: AB_10694568 |
| Flow Cytometry Antibodies                            | Mouse IgG3-FITC | 1:50     | Thermo Fisher, Cat# 11-4742-42, RRID: AB_2043894 |

**Primers**

| Target                          | Forward/Reverse primer (5’-3’) |
|---------------------------------|---------------------------------|
| Sev specific primers (RT-PCR)   | GGA TCA CTA GGT GAT ATC GAG C/ ACC AGA CAA GAG TTT AAG AGA TAT GTA TC |
| KOS/528 bp                      | ATG CAC CGC TAC GAC GTG AGC GC/ ACC TTG ACA ATC CTG ATG TGG |
| Kit4/410 bp                     | TTC CTG CAT GCC AGA GGA GCC C/ AAT GTA TCG AAG GTG CTC AA |
| C-Myc/523 bp                    | TAA CTG ACT AGC AGG CTT GTC G/ TCC ACA TAC AGT CCT GGA TGA TGA TG |
| GAPDH/197 bp                    | GGA GCG AGA TCC CTC CAA AAT/ GGC TGT TGT CAT ACT TCT CAT GG |
| ACVR1 (c. 617G > A)350 bp       | CCA GTC CTT CCT CCT TCT TCC/ AGC AGA TTT TCC AAG TTC CAT C |
### Resource Table

| **Unique stem cell line identifier** | TRNDi012-B |
|--------------------------------------|------------|
| **Alternative name(s) of stem cell line** | NCATS-CL7989 or HT216B |
| **Institution** | National Institutes of Health National Center for Advancing Translational Sciences Bethesda, Maryland, USA |
| **Contact information of distributor** | Dr. Wei Zheng Wei.Zheng@nih.gov |
| **Type of cell line** | iPSC |
| **Origin** | Human |
| **Additional origin info** | Age: 16-year-old  <br> Sex: Female  <br> Ethnicity: Caucasian |
| **Cell Source** | Dermal fibroblasts |
| **Clonality** | Clonal |
| **Method of reprogramming** | Integration-free Sendai viral vectors containing OCT3/4, KLF4, SOX2, and c-MYC pluripotency transcription factors |
| **Genetic Modification** | Yes |
| **Type of Modification** | Hereditary |
| **Associated disease** | Fibrodysplasia ossificans progressiva (FOP) |
| **Gene/locus** | ACVR1, chromosomal location: 2q23-24, c.617G > A; p. R206H |
| **Method of modification** | N/A |
| **Name of transgene or resistance** | N/A |
| **Inducible/constitutive system** | N/A |
| **Date archived/stock date** | 2015 |
| **Cell line repository/bank** | [https://hpscreg.eu/cell-line/TRNDi012-B](https://hpscreg.eu/cell-line/TRNDi012-B) |
| **Ethical approval** | NIGMS Informed Consent Form was obtained from the patient at time of sample submission. Confidentiality Certificate: CC-GM-15-004 |